Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) was upgraded by equities researchers at Leerink Partnrs to a "strong-buy" rating in a report released on Monday,Zacks.com reports.
Several other research firms have also issued reports on RYTM. Stifel Nicolaus lifted their price target on shares of Rhythm Pharmaceuticals from $78.00 to $94.00 and gave the stock a "buy" rating in a report on Thursday, May 29th. Leerink Partners began coverage on shares of Rhythm Pharmaceuticals in a report on Monday. They set an "outperform" rating and a $88.00 price objective on the stock. Bank of America raised shares of Rhythm Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $63.00 price objective on the stock in a report on Monday, April 7th. Canaccord Genuity Group boosted their price objective on shares of Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the company a "buy" rating in a report on Tuesday, April 8th. Finally, JMP Securities reissued a "market outperform" rating and set a $84.00 price objective on shares of Rhythm Pharmaceuticals in a report on Thursday, June 26th. Fourteen investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $79.71.
View Our Latest Research Report on RYTM
Rhythm Pharmaceuticals Stock Performance
NASDAQ:RYTM traded up $23.86 during trading hours on Monday, reaching $89.00. The company's stock had a trading volume of 4,791,941 shares, compared to its average volume of 577,125. The company has a market capitalization of $5.66 billion, a P/E ratio of -31.67 and a beta of 2.26. Rhythm Pharmaceuticals has a 12 month low of $40.61 and a 12 month high of $89.13. The stock has a 50 day moving average price of $62.90 and a two-hundred day moving average price of $58.62.
Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.12). The business had revenue of $37.72 million during the quarter, compared to the consensus estimate of $40.43 million. Rhythm Pharmaceuticals had a negative return on equity of 739.62% and a negative net margin of 123.26%. The business's quarterly revenue was up 25.9% on a year-over-year basis. During the same period last year, the firm earned ($2.35) EPS. As a group, analysts predict that Rhythm Pharmaceuticals will post -4.32 EPS for the current fiscal year.
Insider Activity
In other news, insider Alastair Garfield sold 1,319 shares of the firm's stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $64.81, for a total value of $85,484.39. Following the sale, the insider directly owned 3,126 shares in the company, valued at approximately $202,596.06. This trade represents a 29.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Pamela J. Cramer sold 7,031 shares of Rhythm Pharmaceuticals stock in a transaction on Friday, June 6th. The stock was sold at an average price of $68.05, for a total transaction of $478,459.55. Following the sale, the insider owned 19,209 shares in the company, valued at $1,307,172.45. This represents a 26.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 24,195 shares of company stock valued at $1,599,572 over the last quarter. Company insiders own 6.10% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of RYTM. SBI Securities Co. Ltd. acquired a new position in Rhythm Pharmaceuticals in the fourth quarter valued at $37,000. Charles Schwab Investment Management Inc. increased its stake in Rhythm Pharmaceuticals by 1.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 440,250 shares of the company's stock valued at $24,645,000 after purchasing an additional 6,384 shares during the period. Raymond James Financial Inc. acquired a new position in Rhythm Pharmaceuticals in the fourth quarter valued at $218,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Rhythm Pharmaceuticals during the fourth quarter worth about $341,000. Finally, Swiss National Bank increased its stake in shares of Rhythm Pharmaceuticals by 1.0% during the fourth quarter. Swiss National Bank now owns 90,200 shares of the company's stock worth $5,049,000 after acquiring an additional 900 shares during the period.
Rhythm Pharmaceuticals Company Profile
(
Get Free Report)
Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
Featured Stories

Before you consider Rhythm Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.
While Rhythm Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.